How can adherence to lipid-lowering medication be improved? A systematic review of randomized controlled trials

Family Practice

Volumn 24, Issue 4, 2007, Pages 380-387

  Schedlbauer, Angela ^a   Schroeder, K ^b   Fahey, T ^c  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; COLESTIPOL; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG DOSAGE FORM COMPARISON; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; INTENSIVE CARE; INTERVENTION STUDY; PATIENT ATTITUDE; PATIENT CARE; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SYSTEMATIC REVIEW;

ANTILIPEMIC AGENTS; GREAT BRITAIN; HUMANS; HYPERLIPIDEMIAS; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34548656675     PISSN: 02632136     EISSN: 14602229     Source Type: Journal    
DOI: 10.1093/fampra/cmm030     Document Type: Review

References (31)

1. WHO. Cardiovascular death and disability can be reduced more than 50 percent. http://www.who.int/mediacentre/releases/pr83/en/ (accessed on November 17, 2002).
2. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment. Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
3. Ebrahim S. Detection, adherence and control of hypertension for the prevention of stroke: A systematic review. Health Technol Assess 1998; 2 (11): 1-4.
4. Lewis DK, Robinson J, Wilkinson E. Factors involved in deciding to start preventive treatment: Qualitative study of clinicians' and lay people's attitudes. BMJ 2003; 327: 841-845.
5. Mullen PD. Compliance becomes concordance. BMJ 1997; 314: 691-692.
6. Royal Pharmaceutical Society of Great Britain. From Compliance to Concordance: Towards Shared Goals in Medicine Taking. London: RPS, 1997.
7. Maenpaa H, Heinonen OP, Manninen V. Medication compliance and serum lipid changes in the Helsinki Heart Study. Br J Clin Pharmacol 1991; 32: 409-415.
8. Wei L, Wang J, Thompson P, Wong S, Struthers AD, MacDonald TM. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 2002; 88: 229-233.
9. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid lowering drugs: Evidence from a national cross sectional survey. BMJ 2000; 321: 1322-1325.
10. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. J Am Med Assoc 2002; 288: 455-461.
11. Tsuyuki RT, Bungard TJ. Poor adherence with hypolipidemic drugs: A lost opportunity. Pharmacotherapy 2001; 21: 576-582.
12. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. J Am Med Assoc 2002; 288: 462-467.
13. Stata Corporation. Stata Statistical Software: Release 8.0. College Station, TX: Stata Corporation, 2002.
14. Alderson P. Assessment of study quality. In: The Cochrane Reviewers' Handbook 4.2.2 [updated December 2003]. Section 6. http://www.cochrane.org/resources/handbook/hbook.htm (accessed on January 31, 2004), 2003.
15. Marquez-Contreras E, Casado-Martinez JJ, Lopez A et al. Therapeutic compliance in dyslipidemias. A trial of the efficacy of health education. Aten Primaria 1998; 22: 79-84.
16. Guthrie RM. The effects of postal and telephone reminders on compliance with pravastatin therapy in a national registry: Results of the first myocardial infarction risk reduction program. Clin Ther 2001; 23: 970-980.
17. Marquez-Contreras E, Casado Martinez JJ, Corchado AY et al. Efficacy of an intervention to improve therapy compliance in lipaemia cases. Aten Primaria 2004; 33: 15.
18. Brown BG, Bardsley J, Poulin D et al. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 1997; 80: 111-115.
19. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counselling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization: A randomized, controlled trial. Pharmacotherapy 2000; 20: 410-416.
20. Sweeney ME, Fletcher BJ, Rice CR et al. Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia. Am J Med 1991; 90: 469-473.
21. Poston J, Loh E, Dunham W. The medication use study. Can Pharm J 1998; 131: 31-38.
22. Powell KM, Edgren B. Failure of educational videotapes to improve medication compliance in a health maintenance organization. Am J Health Syst Pharm 1995; 52: 2196-2199.
23. Schectman G, Hiatt J, Hartz A. Telephone contacts do not improve adherence to niacin or bile acid sequestrant therapy. Ann Pharmacother 1994; 28: 29-35.
24. Avorn J, Monette J, Lacour A et al. Persistence of use of lipid-lowering medications: A cross-national study. J Am Med Assoc 1998; 279: 1458-1462.
25. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
26. Maenpaa H, Manninen V, Heinonen OP. Comparison of the digoxin marker with capsule counting and compliance questionnaire methods for measuring compliance to medication in a clinical trial. Eur Heart J 1987; 8: 39-43.
27. Roter DL, Hall JA, Merisca R, Nordstrom B, Cretin D, Svarstad B. Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 1998; 36: 1138-1161.
28. Straka RJ. Patient self-reporting of compliance does not correspond with electronic monitoring: An evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997; 17: 126-132.
29. Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. J Am Med Assoc 2004; 291: 1071-1080.
30. Schroeder K, FTES. Adherence to long-term therapies. J Clin Epidemiol 2004; 57: 2-3.
31. Schedlbauer A, Schroeder K, Fahey T, Peters T. Interventions to improve adherence to lipid lowering medication. Cochrane Database of Systematic Reviews Art. No. CD004371. doi:10.1002/ 14651858.CD004371.pub2.